Price History
Feb 9, 2026 — Aug 5, 2026Investment Snapshot
- Trading 161% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- ROE of 5.2% — below-average profitability
- Revenue growing at 16% annually
Veracyte, Inc. - Common Stock (VCYT) is a Healthcare company operating in Services-Medical Laboratories, listed on the NASDAQ , with a market capitalisation of $3.9 billion . Key value metrics: P/E ratio 54.1, P/B ratio 2.82, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Veracyte, Inc. - Common Stock — Fundamental Analysis Summary
Veracyte, Inc. - Common Stock (VCYT) is currently trading 161% above its Graham Number of $18.70, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 54.1x.
On financial health, VCYT shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and modest return on equity of 5.2% (sector average: -20.1%), and minimal leverage with a debt-to-equity ratio of 0.00.
StockPik's composite Value Score for VCYT is 74/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
VCYT reports a high gross margin of 70.9% (sector average: 37.4%) and a solid operating margin of 11.5%.
VCYT shows revenue growing at 16% year-over-year, with earnings growing at 175%.